HopeStage
Back to all studies
TerminatedNCT01184443

Evaluation of the Efficacy and Safety of Olanzapine for Eating disorders in Children and Adolescents

Medication studyAges 11–17Canada
The study in practice

Understand this study

Who could participate?

Listed age limits: 11 years to 17 years.

Listed locations
OttawaSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateAugust 2010
Recruitment status
Terminated
Enrollment listed in the registry
38
Sponsor
Children's Hospital of Eastern Ontario
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada
Age range
From 11 Years to 17 Years
Official registry ID
NCT01184443
Official title
Show the full official title

Evaluation of the Efficacy and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Children and Adolescents: An Open-label Trial

Recruitment & locations

Terminated

Ottawa

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Children's Hospital of Eastern Ontario, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Olanzapine.

Who can participate?

Listed age limits: 11 years to 17 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies